title: Enhanced monoclonal antibody production in hybridoma cells by LPS and Anti-mIgG.
abstract: This paper reports on a methodology for increasing proliferation and monoclonal antibody (mAb) production in hybridoma cultures. The 55-6 murine B cell hybridoma line (CD40 and CD19-deficient expression) was treated with increasing concentrations of lipopolysaccharide (LPS). Expression of CD69, CD40, and CD19 surface antigens on 55-6 cells did not show significant changes from untreated cells. The specific growth rate decreased at higher concentrations of LPS, but the monoclonal antibody production rate was highest at the highest LPS concentration assayed. These data are in agreement with the lowest growth rate found at this concentration of LPS. Furthermore, cells were cultured with anti-mouse surface immunoglobulin G antibody (anti-mIgG) plus LPS to find out whether LPS-derived signals and anti-mIgG stimuli are synergistic. CD69, CD40, and CD19 expression was greater than for either untreated cells (control culture) or cells stimulated with LPS alone. Moreover, LPS stimulation in combination with anti-mIgG enhanced both the growth rate and IgG2a production over the control culture and cells stimulated with LPS alone. Maximum antibody concentration increased almost 500% compared to the control and about 100% with respect to culture stimulated with LPS alone. The maximum specific IgG2a production rate was about 300% higher than in the control culture and about 30% higher than in culture stimulated only with LPS.
authors.affiliation: Department of Chemical Engineering, University of Almería, 04120 Almería, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Martín-López
authors.forename: Francisco
authors.initials: F
authors.lastname: García-Camacho
authors.forename: Antonio
authors.initials: A
authors.lastname: Contreras-Gómez
authors.forename: Emilio
authors.initials: E
authors.lastname: Molina-Grima
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D015703:Antigens, CD / Q000032:analysis; D018941:Antigens, CD19 / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D019013:CD40 Antigens / Q000032:analysis; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D006825:Hybridomas / Q000187:drug effects / Q000276:immunology*; D037181:Lectins, C-Type; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D000099192:CD69 Antigens
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018941:Antigens, CD19; D000945:Antigens, Differentiation, T-Lymphocyte; D019013:CD40 Antigens; D037181:Lectins, C-Type; D008070:Lipopolysaccharides; D000099192:CD69 Antigens; C048844:anti-IgG